The primary therapeutic applications of this medication generally cover both long-term reproductive planning and the management of certain gynecological conditions. It is commonly used for the prevention of pregnancy and it is relevant in the management of endometriosis-associated pelvic pain.

This use is relevant when supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms. The medication is applied in contraception and relevant for easing the symptom burden in conditions presenting with disruptive manifestations such as heavy or painful periods.

“This application helps improve day-to-day comfort during symptomatic periods by contributing to easing the overall symptom burden.”

This reliable method may assist with maintaining functional stability and supports patients during episodes of heightened discomfort. It may offer supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Endometriosis-Associated Pelvic Pain

Eligibility Map: Who can and cannot use Depo Progevera — Official Regulatory Information

Eligibility scope Populations for whom use is allowed (as stated in label): Females of reproductive potential. Populations for whom use is not recommended (if applicable): Use exceeding two years is generally not recommended unless other birth control methods are considered inadequate. Populations for whom use is contraindicated: Known or suspected pregnancy, active thrombophlebitis, current or past history of cerebral vascular disease, known or suspected malignancy of the breast, significant liver disease, and undiagnosed abnormal genital bleeding. Age-related eligibility rules: Use is permitted in post-menarcheal adolescent females, but the medicine is not indicated for the geriatric population, and use is not established in prepubescent children. Condition-specific eligibility rules: Contraindicated in severe liver disease. For renal impairment, no dosage adjustment is considered necessary. Pregnancy and lactation eligibility status (if explicitly documented): Contraindicated during pregnancy. During lactation, use is generally advised to be delayed until after six weeks postpartum. Eligibility-related restrictions: Use beyond two years requires risk assessment due to the risk of Bone Mineral Density (BMD) loss, especially in women with existing osteoporosis risk factors.

Eligibility classifications (high-level) Eligibility severity classification (as defined in official documents): Contraindicated, Not Recommended, Not Established, Not Indicated. Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information and National Agency Summaries of Product Characteristics (SmPC). Eligibility-context constraints (as defined in official documents): Duration of use, comorbidity presence, and physiological state.

Resulting eligibility structure Official eligibility statements: • Use is contraindicated in females with known pregnancy, active blood clots, or severe liver disease. • The medicine is not recommended as a long-term method beyond two years unless other birth control options are deemed inadequate. • The drug is not indicated for geriatric women, and use in prepubescent children is not established.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define the eligible population as women of reproductive age and establish strict contraindications that prohibit use for individuals with specific conditions, including severe hepatic or thromboembolic disease. Eligibility is further defined by duration limitations that caution against continuous long-term use and by a lack of indication for geriatric or prepubescent populations.

The documented interaction profile for Depo Progevera (Medroxyprogesterone Acetate or MPA) is primarily defined by pharmacokinetic changes related to its metabolic clearance. MPA is metabolized mainly via the CYP3A4 enzyme pathway.

Interaction Type	Interacting Substances
Exposure-Decreasing	Strong or Moderate CYP3A Inducers (e.g., Rifampin, Phenytoin, St. John's Wort)
Exposure-Increasing	Strong CYP3A Inhibitors (e.g., Ketoconazole, Itraconazole)
Specific Drug	Aminoglutethimide

Co-administration with strong CYP3A inducers is a regulatory constraint because it is expected to decrease MPA plasma concentrations, which may result in reduced efficacy. Conversely, strong CYP3A inhibitors are expected to increase MPA plasma concentrations. The specific drug Aminoglutethimide may also significantly depress the serum concentrations of MPA.

Beyond drug-drug interactions, the progestin may affect the results of several laboratory tests, including measurements of coagulation parameters, lipids, and glucose tolerance. For diabetic patients, the regulatory label notes that they should be carefully observed due to the drug's effect on glucose tolerance. No mandatory timing-based separation rules are documented in the official labeling.

Depot medroxyprogesterone acetate (DMPA) is a synthetic progestin and a derivative of the naturally occurring hormone progesterone. Its primary mechanism is mediated by its action as an agonist at the progesterone receptor (PR) in target tissues, including the hypothalamus, pituitary gland, and reproductive tract.

This agonism triggers a cascade within the hypothalamic-pituitary-ovarian (HPO) axis. DMPA inhibits the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which, in turn, suppresses the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary.

The resultant systemic consequence is the prevention of the LH surge, a critical event required for follicular maturation and subsequent ovulation. Additionally, the progestin directly modulates the consistency of the reproductive environment: it increases the viscosity of the cervical mucus, impeding the physiological transit of spermatozoa, and induces a state of endometrial thinning (atrophy), rendering the uterine lining non-receptive to implantation. These three distinct physiological modulations—central gonadotropin suppression, cervical mucus alteration, and endometrial transformation—collectively constitute its mechanistic profile.

How to use Depo-Provera (Medroxyprogesterone Acetate) Contraceptive Injection

Depo-Provera (medroxyprogesterone acetate) Contraceptive Injection (CI) is administered as a deep intramuscular (IM) injection under the supervision of a healthcare professional. The medication must be administered following a strict schedule for maximum contraceptive efficacy.

Official Administration Guidelines

Administration Scope	Regulatory Requirements
Route of Administration	Deep Intramuscular (IM) Injection
Official Dosing Schedule	150 mg administered every 3 months (13 weeks). No weight-based dose adjustment is required.
Preparation	The vial or prefilled syringe must be vigorously shaken immediately before use to ensure the dose is a uniform suspension.
Injection Site	Administer into the gluteal or deltoid muscle using strict aseptic technique. Sites must be rotated with each injection.

Initial and Missed Dose Instructions

The first injection should be given during the first 5 days of a normal menstrual period. For post-partum, non-breast-feeding patients, the first dose is given within the first 5 days post-delivery. For exclusively breast-feeding mothers, administration is recommended during or after the sixth post-partum week.

Missed Dose Rule: If the time between injections is greater than 13 weeks, pregnancy must be ruled out before the next dose is given. The patient should also use a non-hormonal, barrier method of contraception (e.g., condoms) for seven days following the delayed injection.

Research Evidence / Overview of Studies for Depo Provera

---

Evidence for Preventing Pregnancy (Contraception)

Research has explored the role of the injection for the prevention of pregnancy. This research was evaluated in large-scale clinical trials and non-comparative studies that formed the basis for its authorization by regulatory bodies worldwide. These studies were designed to track pregnancy outcomes and subject adherence across a wide group of women. Research examined the primary study outcomes over defined time intervals, tracking outcomes such as the occurrence of pregnancy (reported using measures like the Pearl Index) and the rate at which subjects continued using the method.

In addition to tracking pregnancy outcomes, studies monitored the underlying physiological changes. This includes research examining temporary physiological imbalance, specifically the suppression of ovulation, which was observed in the study populations. Researchers also tracked the drug's presence in the body over time (pharmacokinetics) to track patterns in the levels measured. The findings describe patterns observed in the studies and contribute to the body of evidence.

Evidence is limited regarding continuous use extending beyond a certain duration, such as two years. Regulatory reviews emphasize that the key data is often based on short-to-intermediate follow-up durations. Furthermore, studies monitored the time it may take for the body’s natural ovulatory function to resume after the final injection is received, but this return time was associated with variation among individuals.

---

Evidence for Managing Endometriosis-Associated Pelvic Pain

Research has explored the injection in the context of managing conditions where symptoms may vary in intensity, specifically for outcomes related to physical discomfort tied to endometriosis. This evidence largely comes from Randomized Controlled Trials (RCTs) and systematic reviews where the injection was evaluated in women with confirmed symptomatic endometriosis. These studies often tracked symptom patterns over defined time intervals.

The research examined the injection's effects during periods of heightened symptoms by tracking patient-reported outcomes describing perceived discomfort. Specific outcomes related to physical discomfort—such as painful periods (dysmenorrhea), non-menstrual pelvic pain, and pain during intercourse—were monitored using standardized scales. In these comparative trials, the injection was observed in relation to other approved therapies. The research highlights changes measured during the study period in these discomfort levels, and these findings help contextualize how patients reported their experience.

The data show patterns related to symptom changes over the short-term study periods, typically around six months. However, the evidence is limited for extended use due to regulatory precautions related to long-term physiological monitoring. Furthermore, findings were mixed in trials comparing the injection directly against all alternative treatments, meaning comparative evidence is lacking for a full assessment of its place among all options. Reports documented that some subjects discontinued participation; subject reports sometimes involved changes in bleeding patterns, which was observed in some studies and contributed to less complete long-term follow-up data.

---

Long-Term Research and Follow-up

Research explored the need for extended follow-up beyond the initial efficacy trials to understand the full scope of use. Studies monitored the impact of the active ingredient on certain physiological markers, such as those related to bone density, over prolonged periods. This monitoring was associated with requirements to monitor long-term continuous administration.

These long-term studies contribute to the broader evidence landscape by tracking outcomes beyond the initial two years of use. For women who discontinue the treatment, research has explored the time required for their cycles and fertility to return to their pre-treatment state. However, the long-term effects are not fully established across all subgroups and outcomes, emphasizing that research is ongoing in this domain.

---

Research in Specific Populations and Subgroups

The clinical trials used in research contexts involving fluctuating or unstable symptoms included a broad population of women of reproductive potential, which spans both adult and adolescent age groups. Studies explored how primary study outcomes and other physiological changes were related to factors like body mass index (BMI). These focused analyses contribute to the broader evidence landscape by providing context for how results may vary within specific demographic categories.

However, data for certain groups remain insufficient for conclusive statements. For instance, subgroup findings are uncertain regarding the long-term changes in specific physiological markers in adolescents compared to older adults, as the follow-up durations were limited in certain reports for these cohorts. Consequently, data are still emerging for some of these specialized groups.

---

What Research Gaps and Uncertainties Remain

The evidence base, while detailed in certain areas, still contains gaps. Long-term effects are not fully established regarding use exceeding two years, leading to caution and the need for continued observation. Evidence quality varies across studies, particularly in older trials for endometriosis, where differences in how pain was measured led to findings were mixed when compared across multiple research efforts.

Furthermore, comparative evidence is lacking in some areas, particularly concerning direct head-to-head trials against every single alternative therapy available for both contraception and endometriosis management. Research does not determine whether an individual will respond similarly to the group patterns. The evidence highlights what is known — and what is still uncertain — about the medication's overall profile.

Key Studies & References

1. WHO Electronic Essential Medicines List (eEML) - Medroxyprogesterone acetate (Informs efficacy, return to fertility, and BMD context)
2. NICE guideline NG73: Endometriosis: diagnosis and management (Informs evidence for pain management)

Common questions about Depo Progevera (FAQ)

Q: Is it true that I can't take this if I have high blood pressure?

A: Official product information does not list high blood pressure itself as a contraindication (a specific reason the drug should not be used). However, official labeling notes that because the medication may cause fluid retention, conditions influenced by fluid changes, such as existing cardiac or renal dysfunction, require careful observation by a healthcare provider.

Q: Will this injection make my vision blurry or cause other eye problems?

A: The official labeling describes certain visual changes as serious signs that require medical evaluation. Regulatory guidance indicates that if sudden partial or complete loss of vision occurs, the medication must be withdrawn under medical supervision. Withdrawal is also necessary if sudden bulging of the eye (proptosis), double vision (diplopia), or signs of retinal problems are observed.

Q: What happens if I smoke? Does that make me ineligible?

A: The product label discusses tobacco use in the context of known risk factors for osteoporosis. Official documentation states that risk factors for bone mineral density loss, such as chronic tobacco use, are a key consideration in the overall risk-benefit analysis of the medication.

Q: Do I need to check my liver function tests (LFTs) while on this?

A: Official regulatory documents state that the medication is contraindicated (must not be used) in patients with known significant liver disease. Furthermore, the documents state that the medication must be discontinued if symptoms like jaundice (yellowing of the skin or eyes) or disturbances of liver function develop.

Q: Is this injection free of estrogen?

A: Yes, the official product description identifies the medication as a progestin formulation. The active ingredient, medroxyprogesterone acetate, is a synthetic hormone that works by mimicking the action of the natural hormone progesterone. This formulation is described as a progestin-only product.

Q: I heard I could lose my hair while taking this. Is that a side effect?

A: Official regulatory documentation includes reports of hair loss and thinning of hair among the postmarketing adverse reactions associated with this medication. These are effects that have been reported by patients after the product was made available to the public.

Q: Are there any antibiotics that will make this shot less effective?

A: Official drug interaction information notes that certain medications and herbal products that induce specific liver enzymes (like CYP3A4) may decrease the effectiveness of contraceptive products. The regulatory text indicates that if a person is taking drugs known to cause this enzyme induction, the use of an alternative or back-up method of contraception is recommended.

Q: Is there a Black Box Warning for this medicine?

A: Yes, the official label contains a Boxed Warning (sometimes called a Black Box Warning) regarding the risk of Loss of Bone Mineral Density (BMD). The warning states that bone loss increases the longer the medication is used and may not be completely reversible. For contraception, the medication is generally not recommended for long-term use (over two years) unless other options are considered inadequate.

Official Storage and Disposal Requirements

Depo-Provera (Medroxyprogesterone Acetate Injectable Suspension) must be stored strictly according to the conditions defined in official regulatory labeling.

Storage Conditions

Requirement	Specific Instruction
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Prohibitions	Do not refrigerate or freeze the product.
Protection	Must be protected from light and stored in the original container.
Handling	The suspension must be shaken vigorously just before use to ensure the dose is uniform.

Disposal and Safety

The medicine must be stored out of the reach and sight of children. Unused or expired Depo-Provera must be disposed of in accordance with local requirements for pharmaceutical waste. Regulatory documents generally state that the product should not be disposed of via household waste or wastewater.